Dapagliflozin didn't significantly change the amount of fluid in the bloodstream of people with type 2 diabetes and healthy kidneys, even after two weeks of treatment.
Scientific Claim
In patients with type 2 diabetes and preserved kidney function on a standardized sodium intake, dapagliflozin treatment was not associated with significant changes in plasma volume, with mean changes of -0.19 L (95% CI: -0.9 to 0.5) after 2-4 days and -0.45 L (95% CI: -1.1 to 0.2) after 12-14 days.
Original Statement
“Mean (SD) plasma volume at baseline was 3.75 (0.8) L, remained stable at ST (mean change −0.19 L [95% CI −0.9, 0.5]; P = 0.58) (Fig. 2A) and tended to be lower at ET (mean change −0.45 L [−1.1, 0.2]; P = 0.16).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design is nonrandomized and lacks a control group, so only association can be inferred. The claim correctly uses 'associated with' to reflect this limitation.